Hanmi Science Co (008930.KS) Stock Price

Hanmi Science Co Price

KOSDAQ·CLOSED
44,650.00KRW+2,950.00 (+6.83 %)
Market closed

Revenue has compounded at 6.4% per year over the past 19 years to 1.28 T KRW. Earnings per share have declined at 5.0% per year over the last 19 years. Hanmi Science Co's net margin stands at 4.6%, up from 2.6% several years earlier. Hanmi Science Co currently offers a dividend yield of about 0.67%. The payout ratio is around 34% of earnings. The stock trades about 73% above its 52-week low.

Hanmi Science Co stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Hanmi Science Co over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Hanmi Science Co stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Hanmi Science Co's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Hanmi Science Co Stock Price History
DateHanmi Science Co Price
8/7/202644,650.00 KRW
8/6/202641,700.00 KRW
8/5/202640,450.00 KRW
8/4/202639,200.00 KRW
8/3/202636,300.00 KRW
7/31/202636,200.00 KRW
7/30/202634,750.00 KRW
7/29/202632,300.00 KRW
7/28/202633,950.00 KRW
7/27/202635,250.00 KRW
7/24/202634,600.00 KRW
7/23/202634,350.00 KRW
7/22/202633,250.00 KRW
7/21/202633,000.00 KRW
7/20/202632,950.00 KRW
7/16/202632,700.00 KRW
7/15/202632,500.00 KRW
7/14/202631,200.00 KRW
7/13/202633,650.00 KRW
7/10/202633,150.00 KRW
7/9/202632,350.00 KRW
7/8/202633,950.00 KRW
7/7/202631,650.00 KRW
7/6/202631,500.00 KRW
7/3/202631,200.00 KRW
7/2/202630,600.00 KRW
7/1/202630,400.00 KRW
6/30/202629,950.00 KRW
6/29/202628,650.00 KRW
6/26/202625,850.00 KRW
6/25/202628,100.00 KRW
6/24/202627,700.00 KRW
6/23/202627,350.00 KRW
6/22/202628,400.00 KRW
6/19/202629,150.00 KRW
6/18/202630,250.00 KRW
6/17/202631,600.00 KRW
6/16/202630,750.00 KRW
6/15/202630,750.00 KRW
6/12/202630,700.00 KRW
6/11/202629,550.00 KRW
6/10/202629,500.00 KRW
6/9/202629,700.00 KRW
6/8/202628,450.00 KRW
6/5/202631,450.00 KRW
6/4/202632,300.00 KRW
6/2/202632,600.00 KRW
6/1/202633,650.00 KRW
5/29/202631,800.00 KRW
5/28/202631,700.00 KRW
5/27/202632,700.00 KRW
5/26/202633,200.00 KRW
5/22/202633,950.00 KRW
5/21/202631,950.00 KRW
5/20/202631,525.00 KRW
5/19/202633,450.00 KRW
5/18/202634,150.00 KRW
5/15/202635,900.00 KRW
5/14/202635,350.00 KRW
5/13/202634,600.00 KRW
5/12/202636,300.00 KRW
5/11/202635,200.00 KRW
5/8/202637,100.00 KRW
5/7/202636,600.00 KRW
5/6/202636,750.00 KRW
5/4/202638,050.00 KRW
4/30/202637,700.00 KRW
4/29/202638,000.00 KRW
4/28/202638,500.00 KRW
4/27/202638,750.00 KRW
4/24/202639,000.00 KRW
4/23/202638,800.00 KRW
4/22/202638,650.00 KRW
4/21/202639,250.00 KRW
4/20/202639,950.00 KRW
4/17/202640,100.00 KRW
4/16/202640,150.00 KRW
4/15/202639,350.00 KRW
4/14/202638,550.00 KRW
4/13/202638,350.00 KRW
4/10/202638,900.00 KRW
4/9/202639,350.00 KRW
4/8/202638,550.00 KRW
4/7/202638,000.00 KRW
4/6/202638,000.00 KRW
4/3/202637,600.00 KRW
4/2/202637,100.00 KRW
4/1/202638,000.00 KRW
3/31/202637,100.00 KRW
3/30/202637,500.00 KRW
3/27/202638,400.00 KRW
3/26/202637,950.00 KRW
3/25/202637,700.00 KRW
3/24/202636,700.00 KRW
3/23/202635,800.00 KRW
3/20/202638,450.00 KRW
3/19/202637,600.00 KRW
3/18/202638,400.00 KRW
3/17/202638,150.00 KRW
3/16/202636,550.00 KRW
3/13/202637,150.00 KRW
3/12/202638,100.00 KRW
3/11/202638,050.00 KRW
3/10/202638,000.00 KRW
3/9/202637,200.00 KRW
3/6/202639,400.00 KRW
3/5/202638,350.00 KRW
3/4/202634,900.00 KRW
3/3/202640,450.00 KRW
2/27/202643,600.00 KRW
2/26/202647,000.00 KRW
2/25/202646,700.00 KRW
2/24/202650,700.00 KRW
2/23/202642,750.00 KRW
2/20/202642,550.00 KRW
2/19/202643,350.00 KRW
2/13/202641,550.00 KRW
2/12/202641,900.00 KRW
2/11/202642,150.00 KRW
2/10/202645,000.00 KRW
2/9/202647,900.00 KRW
2/6/202646,450.00 KRW
2/5/202646,000.00 KRW
2/4/202644,700.00 KRW
2/3/202642,600.00 KRW
2/2/202639,300.00 KRW
1/30/202642,500.00 KRW
1/29/202642,600.00 KRW
1/28/202640,600.00 KRW
1/27/202639,850.00 KRW
1/26/202640,650.00 KRW
1/23/202640,400.00 KRW
1/22/202639,100.00 KRW
1/21/202638,750.00 KRW
1/20/202640,400.00 KRW
1/19/202638,550.00 KRW
1/16/202636,850.00 KRW
1/15/202636,850.00 KRW
1/14/202636,200.00 KRW
1/13/202636,550.00 KRW
1/12/202638,550.00 KRW
1/9/202638,400.00 KRW
1/8/202637,000.00 KRW
1/7/202637,700.00 KRW
1/6/202638,000.00 KRW
1/5/202637,950.00 KRW
1/2/202636,500.00 KRW
12/30/202536,250.00 KRW
12/29/202536,750.00 KRW
12/26/202537,000.00 KRW
12/24/202536,800.00 KRW
12/23/202537,200.00 KRW
12/22/202537,150.00 KRW
12/19/202537,450.00 KRW
12/18/202537,100.00 KRW
12/17/202537,400.00 KRW
12/16/202537,500.00 KRW
12/15/202537,850.00 KRW
12/12/202538,050.00 KRW
12/11/202537,250.00 KRW
12/10/202536,950.00 KRW
12/9/202536,850.00 KRW
12/8/202536,650.00 KRW
12/5/202536,950.00 KRW
12/4/202537,100.00 KRW
12/3/202537,300.00 KRW
12/2/202537,000.00 KRW
12/1/202538,700.00 KRW
11/28/202538,850.00 KRW
11/27/202538,000.00 KRW
11/26/202538,500.00 KRW
11/25/202537,450.00 KRW
11/24/202537,600.00 KRW
11/21/202537,850.00 KRW
11/20/202538,700.00 KRW
11/19/202538,000.00 KRW
11/18/202538,550.00 KRW
11/17/202540,450.00 KRW
11/14/202540,750.00 KRW
11/13/202541,600.00 KRW
11/12/202540,950.00 KRW
11/11/202539,600.00 KRW
11/10/202539,800.00 KRW
11/7/202539,000.00 KRW
11/6/202539,400.00 KRW
11/5/202540,000.00 KRW
11/4/202540,500.00 KRW
11/3/202539,300.00 KRW
10/31/202539,400.00 KRW
10/30/202538,200.00 KRW
10/29/202538,550.00 KRW
10/28/202539,750.00 KRW
10/27/202540,900.00 KRW
10/24/202537,400.00 KRW
10/23/202537,650.00 KRW
10/22/202538,300.00 KRW
10/21/202537,750.00 KRW
10/20/202538,100.00 KRW
10/17/202537,450.00 KRW
10/16/202537,600.00 KRW
10/15/202536,750.00 KRW
10/14/202536,300.00 KRW
10/13/202536,550.00 KRW
10/10/202537,350.00 KRW
10/2/202538,100.00 KRW
10/1/202538,400.00 KRW
9/30/202538,900.00 KRW
9/29/202538,750.00 KRW
9/26/202538,700.00 KRW
9/25/202539,050.00 KRW
9/24/202540,750.00 KRW
9/23/202541,750.00 KRW
9/22/202541,300.00 KRW
9/19/202541,600.00 KRW
9/18/202540,300.00 KRW
9/17/202539,200.00 KRW
9/16/202540,000.00 KRW
9/15/202539,350.00 KRW
9/12/202539,250.00 KRW
9/11/202538,700.00 KRW
9/10/202538,850.00 KRW
9/9/202538,700.00 KRW
9/8/202539,250.00 KRW
9/5/202539,300.00 KRW
9/4/202540,000.00 KRW
9/3/202539,850.00 KRW
9/2/202541,200.00 KRW
9/1/202541,000.00 KRW
8/29/202541,050.00 KRW
8/28/202542,550.00 KRW
8/27/202541,550.00 KRW
8/26/202541,000.00 KRW
8/25/202541,050.00 KRW
8/22/202540,950.00 KRW
8/21/202540,800.00 KRW
8/20/202541,100.00 KRW
8/19/202542,700.00 KRW
8/18/202542,850.00 KRW
8/14/202541,850.00 KRW
8/13/202542,150.00 KRW
8/12/202541,800.00 KRW
8/11/202542,300.00 KRW
Access this data via the Eulerpool API
Get Free API Key

Hanmi Science Co Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2017
652.32 B KRW
13.97 B KRW
30.07 B KRW
Jan 1, 2018
708.00 B KRW
11.00 B KRW
18.02 B KRW
Jan 1, 2019
816.62 B KRW
16.15 B KRW
30.74 B KRW
Jan 1, 2020
857.38 B KRW
25.15 B KRW
22.60 B KRW
Jan 1, 2021
950.16 B KRW
28.75 B KRW
42.94 B KRW
Jan 1, 2022
1.05 T KRW
28.11 B KRW
69.21 B KRW
Jan 1, 2023
1.25 T KRW
57.01 B KRW
115.12 B KRW
Jan 1, 2024
1.28 T KRW
37.96 B KRW
59.42 B KRW

Hanmi Science Co Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 8, 2026, 9:33 AM
 
REVENUET KRW
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB KRW
EBITB KRW
EBIT MARGIN%
NET INCOMEB KRW
NET INCOME GROWTH%
DIV.KRW
DIV. GROWTH%
SHARESM
2009201020112012201320142015201620172018201920202021202220232024
0.690.010.020.020.220.530.780.670.650.710.820.860.951.051.251.28
14.04-98.4157.9916.33992.20141.7945.74-14.34-1.958.5315.344.9910.8210.0919.302.85
60.9991.0194.7795.7125.7012.8527.8912.8014.0513.0513.2714.0813.9715.3318.8818.90
422.079.9916.4419.3156.6468.48216.5885.1591.6492.41108.33120.72132.77160.37235.59242.61
74.942.733.074.156.829.29147.0715.0713.9711.0016.1525.1528.7528.1157.0137.96
10.8324.8717.7220.553.101.7418.942.262.141.551.982.933.032.694.572.96
50.536.98-14.6912.489.5821.31178.527.9430.0718.0230.7422.6042.9469.21115.1259.42
-29.38-86.19-310.53-184.94-23.25122.51737.65-95.55278.80-40.0770.60-26.4890.0061.1766.34-48.38
595.24318.74––––500.00414.94196.08196.08200.00196.08196.08196.08200.00300.00
–-46.45–––––-17.01-52.74–2.00-1.96––2.0050.00
16.0054.0066.0066.0069.0069.0065.0066.0064.0066.0066.0066.0068.6268.4967.9667.72
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Hanmi Science Co generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Hanmi Science Co retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Hanmi Science Co's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Hanmi Science Co has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Hanmi Science Co's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Hanmi Science Co stock margins

The Hanmi Science Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Hanmi Science Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Hanmi Science Co.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2017
14.05 %
2.14 %
4.61 %
Jan 1, 2018
13.05 %
1.55 %
2.55 %
Jan 1, 2019
13.27 %
1.98 %
3.76 %
Jan 1, 2020
14.08 %
2.93 %
2.64 %
Jan 1, 2021
13.97 %
3.03 %
4.52 %
Jan 1, 2022
15.33 %
2.69 %
6.62 %
Jan 1, 2023
18.88 %
4.57 %
9.23 %
Jan 1, 2024
18.90 %
2.96 %
4.63 %

Hanmi Science Co Stock Revenue, EBIT, Earnings per Share

The Hanmi Science Co earnings per share therefore indicates how much revenue Hanmi Science Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2017
10,192.56 KRW
218.30 KRW
469.83 KRW
Jan 1, 2018
10,727.20 KRW
166.62 KRW
273.03 KRW
Jan 1, 2019
12,373.02 KRW
244.62 KRW
465.79 KRW
Jan 1, 2020
12,990.65 KRW
381.09 KRW
342.44 KRW
Jan 1, 2021
13,846.88 KRW
419.02 KRW
625.80 KRW
Jan 1, 2022
15,272.20 KRW
410.42 KRW
1,010.45 KRW
Jan 1, 2023
18,363.50 KRW
838.96 KRW
1,694.06 KRW
Jan 1, 2024
18,953.33 KRW
560.56 KRW
877.52 KRW

Hanmi Science Co business model & stock analysis

Hanmi Science Co Ltd is a South Korean company specializing in the manufacturing of pharmaceutical products, biologics, and medical devices. The company was founded in 1973 as a chemical company and obtained the license for drug manufacturing in 1990, expanding its product range to include pharmaceuticals. Today, the company's business model includes three main areas: research and development, manufacturing and sales of drugs, and sales of medical devices. Hanmi aims to develop and produce innovative and high-quality products to improve people's health worldwide. In the field of research and development, Hanmi Science is a leading company. It specializes in the research and development of novel drugs and biologics. The company has an impressive track record in the development and marketing of innovative drugs for the treatment of diabetes, cancer, and rare diseases. This includes a range of biosimilars produced using biotechnological methods that are more affordable compared to original medical substances. Hanmi also has a state-of-the-art production infrastructure that meets the highest quality standards and ensures reliable supply. In the field of drug manufacturing, the company produces generics and biosimilars that are sold in more than 50 countries worldwide. Hanmi also specializes in the production of chemotherapeutics and parenteral drugs that have proven efficacy and safety. The medical device sales division focuses on marketing high-quality medical devices, including diagnostic and monitoring devices used in the medical field. Hanmi also distributes a range of medical consumables, including transfusion sets, syringes, infusion sets, and catheters. Hanmi Science Co Ltd offers a wide range of products that can be categorized into various categories. Among the pharmaceutical products are antidiabetic drugs, anticancer agents, antidepressants, antibiotics, antiviral medications, and products for the treatment of rare diseases. The portfolio also includes biosimilars of botulinum toxin, insulin, and humiderm among the biologics. Overall, Hanmi Science Co Ltd holds a strong position in the South Korean market and has also established a good reputation internationally. With its focus on research and development and the production of high-quality drugs and medical devices, the company has a promising future.

Hanmi Science Co SWOT Analysis

Strengths

Hanmi Science Co Ltd has a strong emphasis on research and development, allowing them to continuously innovate and develop new products. This gives them a competitive advantage in the market and enables them to meet the evolving needs of their customers.

The company offers a wide range of products in various therapeutic areas, including pharmaceuticals, vaccines, and medical devices. This diversified portfolio helps them cater to different customer segments and provides stability in their revenue streams.

Hanmi Science Co Ltd has established a strong market presence, both domestically and internationally. Their products are well-regarded, and they have built a reputation for quality and reliability. This helps them attract and retain customers, as well as forge strategic partnerships.

Weaknesses

While Hanmi Science Co Ltd has a robust product portfolio, they still rely heavily on a limited number of key products for a significant portion of their revenues. This makes them vulnerable to market fluctuations and increased competition in those specific product categories.

Compared to some of their larger competitors, Hanmi Science Co Ltd has a relatively small market share. This can limit their bargaining power with suppliers and customers, as well as hinder their ability to invest in new technologies or expand their market reach.

Opportunities

The company has an opportunity to expand its presence in emerging markets, where there is a growing demand for healthcare products. Additionally, exploring international markets further can help Hanmi Science Co Ltd tap into new customer bases, diversify their revenue streams, and reduce dependence on any one market.

Forming strategic partnerships and collaborations with other pharmaceutical companies or research institutions can provide Hanmi Science Co Ltd with access to new technologies, resources, and markets. These alliances can accelerate their product development process and enable them to stay ahead of competitors.

Threats

The pharmaceutical and healthcare industry is highly competitive, with numerous players vying for market share. Hanmi Science Co Ltd faces competition from both domestic and international companies, which can pose a threat to their market position and profitability.

Operating in the pharmaceutical sector involves stringent regulations and compliance requirements. Changes in government policies, pricing regulations, or delays in product approvals can create challenges for Hanmi Science Co Ltd, impacting their ability to bring new products to the market and affecting their revenue streams.

Rapid advancements in technology and the emergence of alternative treatment options can pose a threat to traditional pharmaceutical companies like Hanmi Science Co Ltd. They need to stay updated with the latest trends and invest in research to ensure their products remain relevant and competitive in the market.

Hanmi Science Co Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Hanmi Science Co historical P/E ratio, EBIT multiple, and P/S ratio

Hanmi Science Co annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Hanmi Science Co shares outstanding

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2017
64.00 M Stocks
Jan 1, 2018
66.00 M Stocks
Jan 1, 2019
66.00 M Stocks
Jan 1, 2020
66.00 M Stocks
Jan 1, 2021
68.62 M Stocks
Jan 1, 2022
68.49 M Stocks
Jan 1, 2023
67.96 M Stocks
Jan 1, 2024
67.72 M Stocks

Hanmi Science Co stock splits

In Hanmi Science Co's history, there have been no stock splits.

Hanmi Science Co Dividend History

27 years of dividend payments · 2 consecutive increases

YearAnnual DividendYoY ChangePayments
2026300.00KRWYTD—1×
Mar 30, 2026300.00KRW↑ 50.0%1/1
2024300.00KRW↑ 50.0%2×
2023200.00KRW↑ 2.0%1×
2022196.08KRW 0.0%1×
2021196.08KRW 0.0%1×
2020196.08KRW↓ 2.0%1×
2019200.00KRW↑ 2.0%1×
2018196.08KRW 0.0%1×
2017196.08KRW↓ 52.7%1×
2016414.94KRW↓ 17.0%—

Hanmi Science Co dividend payout ratio

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2017
38.56 %
Jan 1, 2018
67.67 %
Jan 1, 2019
39.67 %
Jan 1, 2020
55.04 %
Jan 1, 2021
31.33 %
Jan 1, 2022
19.79 %
Jan 1, 2023
11.81 %
Jan 1, 2024
34.19 %
Price targets and forecasts for Hanmi Science Co are not yet available.

EESG©

Eulerpool ESG Scorecard© for the Hanmi Science Co stock

5/100
6
Environment
7
Social
4
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Hanmi Science Co shareholder structure

% Name
6.77529%
Im (Jong Yun)
Im (Jong Yun)
0.83784%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
0.53660%
Samsung Asset Management Co., Ltd.
Samsung Asset Management Co., Ltd.
0.52425%
Im (Seong Yeon)
Im (Seong Yeon)
0.45030%
Mirae Asset Global Investments Co., Ltd.
Mirae Asset Global Investments Co., Ltd.
0.37302%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.

Hanmi Science Co Beneficial Ownership Filings (SEC 13D/G)

Free Float
19.9%
Float Shares
-
Shares Outstanding
-

Hanmi Science Co Executives and Management Board

23 members · avg. age 55 · 19 % women

JY

Ms. Ju Hyeon Yim (49)

Co-President, Director · since 2009

1.15 B KRW

Management

JY

Mr. Jong Yun Yim (51)

Co-President, Director · since 2009

1.13 B KRW
JY

Mr. Jong Hun Yim (46)

Chief Executive Officer, Director · since 2009

–
SS

Mr. Seong Jae Shin (58)

Managing Director

–
CC

Mr. Chang Ju Choi (50)

Assistant Managing Director

–
SG

Mr. Sun Gi Gwon (56)

Assistant Managing Director

–
DJ

Mr. Dae Su Jung (52)

Assistant Managing Director

–

Board of Directors

YC

Mr. Yin Yeong Choi (53)

Other Non-Executive Director

–
WL

Mr. Wu Hyeon Lee (56)

Director

–
DS

Dong Guk Shin (74)

Director

–
BB

Ms. Bo Gyeong Bae (66)

Other Non-Executive Director

–
GG

Mr. Gyu Chan Gwon (53)

Other Non-Executive Director

–
TG

Mr. Tae Seon Gwak (65)

Non-Executive Independent Director

–

Hanmi Science Co Supply Chain

Hanmi Science Co Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
1 companies
#Nameβ 1YTrend
1
JVM
Supplier·Customer·Machinery·KR
0.37
0.74
0.76
-0.02
0.68
0.07
0.44

Frequently asked questions about Hanmi Science Co

The business model of Hanmi Science Co Ltd., a South Korean company, revolves around its expertise in the field of biotechnology. Hanmi Science focuses on the development, manufacturing, and distribution of innovative pharmaceutical products. The company is committed to researching and creating cutting-edge drugs and therapies to address various medical conditions and improve patient outcomes. With a strong emphasis on research and development, Hanmi Science aims to enhance global healthcare by delivering novel treatment options to customers worldwide.

Hanmi Science Co Ltd is primarily active in the pharmaceutical and healthcare industries.

Hanmi Science Co Ltd faces competition from various companies in the market. Some of its main competitors include CJ Healthcare Corp, SK Biopharmaceuticals Co Ltd, and Yuhan Corporation. These competitors are also prominent players in the pharmaceutical and biotechnology industry.

Hanmi Science Co Ltd is a leading company in the healthcare industry. Established in 1973, Hanmi Science Co Ltd has a rich history of over four decades. The company focuses on research, development, and manufacturing of innovative medical devices and pharmaceutical products. With a strong commitment to improving global healthcare, Hanmi Science Co Ltd has made significant contributions to the industry. They have formed strategic partnerships and collaborations with renowned companies to enhance their capabilities and expand their global presence. Hanmi Science Co Ltd's dedication to quality, innovation, and customer satisfaction has positioned them as a trusted and reliable name in the healthcare sector.

Hanmi Science Co Ltd has achieved several significant milestones in its corporate history. The company made its debut in 1973 as a small chemical trading business and has since evolved into a leading global provider of pharmaceutical and healthcare solutions. Hanmi Science Co Ltd successfully developed and launched its first original drug, LUSEDRA, in 2008, marking a major advancement in the pharmaceutical sector. Additionally, the company has established numerous strategic partnerships and collaborations with global pharmaceutical giants, enabling it to enhance its research and development capabilities. Hanmi Science Co Ltd continues to foster innovation, expand its product pipeline, and deliver breakthrough treatments to improve patient outcomes.

Hanmi Science Co Ltd is primarily present in South Korea.

Hanmi Science Co Ltd represents values of innovation, excellence, and customer satisfaction. With a strong corporate philosophy focused on pioneering new technologies and providing top-notch services, Hanmi Science Co Ltd aims to meet the ever-evolving needs of its clients. By prioritizing research and development, the company strives to deliver cutting-edge solutions in the fields of biotechnology and pharmaceuticals. With a commitment to ethical practices, Hanmi Science Co Ltd also emphasizes integrity and social responsibility in its operations. Through its dedication to these values and its forward-thinking approach, Hanmi Science Co Ltd continues to make significant contributions to the industry.

Converted at the current exchange rate, the Hanmi Science Co share trades at 27.35 EUR (44,650.00 KRW).

Hanmi Science Co Ltd is a leading company in the pharmaceutical industry that specializes in the research and development of innovative drugs and medical devices. The company offers a wide range of products and services divided into various business areas.

The revenue cannot currently be calculated for Hanmi Science Co.

The profit cannot currently be calculated for Hanmi Science Co.

The P/E ratio cannot be calculated for Hanmi Science Co at the moment.

The P/S cannot be calculated for Hanmi Science Co currently.

The Eulerpool Quality Score for Hanmi Science Co is 6/10.

The ISIN of Hanmi Science Co is KR7008930000. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Hanmi Science Co is 008930.KS. The ticker symbol is used to trade Hanmi Science Co shares on the stock exchange.

Over the past 12 months, Hanmi Science Co paid a dividend of 300.00 KRW . This corresponds to a dividend yield of about 0.67 %. For the coming 12 months, Hanmi Science Co is expected to pay a dividend of 500.00 KRW.

The current dividend yield of Hanmi Science Co is 0.67 %.

Hanmi Science Co pays a dividend, distributed in the months of , , , .

Hanmi Science Co paid dividends every year for the past 0 years.

For the upcoming 12 months, dividends amounting to 500.00 KRW are expected. This corresponds to a dividend yield of 1.20 %.

Hanmi Science Co is assigned to the 'Health' sector.

In the year 2025, Hanmi Science Co distributed 200 KRW as dividends.

The dividends of Hanmi Science Co are distributed in KRW.

All fundamentals and in-depth analysis of Hanmi Science Co

Our stock analysis for Hanmi Science Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hanmi Science Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Hanmi Science Co Stock
Hanmi Science Co Revenue→
Hanmi Science Co Stock
Hanmi Science Co Net Income→
Hanmi Science Co Stock
Hanmi Science Co P/E→
Hanmi Science Co Stock
Hanmi Science Co P/S→
Hanmi Science Co Stock
Hanmi Science Co EBIT→
Hanmi Science Co Stock
Hanmi Science Co Dividend→
Hanmi Science Co Stock
Hanmi Science Co Directors Dealings→
Hanmi Science Co Stock
Hanmi Science Co Stocks→
Hanmi Science Co Stock
Hanmi Science Co Market capitalization→
Hanmi Science Co Stock
Hanmi Science Co Debt→
Hanmi Science Co Stock
Hanmi Science Co Liabilities→
Hanmi Science Co Stock
Hanmi Science Co Equity→
Hanmi Science Co Stock
Hanmi Science Co AAQS→
Hanmi Science Co Stock
Hanmi Science Co Employees→
Hanmi Science Co Stock
Hanmi Science Co ROE→
Hanmi Science Co Stock
Hanmi Science Co ROA→
Hanmi Science Co Stock
Hanmi Science Co ROCE→
Hanmi Science Co Stock
Hanmi Science Co News→
Hanmi Science Co Stock
Hanmi Science Co Analyst Price Targets→

Health Stocks

Hans BiomedHanmi Pharm CoHansa BiopharmaHangzhou Tigermed Consulting CoHanshang Group CoHangzhou TianMuShan Pharmaceutical Enterprise CoHansoh Pharmaceutical Group CompanyHangzhou Biotest Biotech CoHapvida Participacoes e InvestimentosHangzhou Bio-Sincerity Pharma-Tech CoHarbin Fuerjia Technology CoHangzhou Alltest Biotech CoAll Stocks A–Z →